|
🐜
|
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
21 auth.
R. Finn,
S. Qin,
M. Ikeda,
P. Galle,
M. Ducreux,
Tae-You Kim,
M. Kudo,
V. Breder,
P. Merle,
A. Kaseb,
...
Daneng Li,
W. Verret,
Derek-Zhen Xu,
Sairy G. Hernandez,
Juan Liu,
Chen Huang,
S. Mulla,
Yulei N. Wang,
Ho Yeong Lim,
A. Zhu,
A. Cheng
|
12 |
2020 |
12
🐜
|
|
🐜
|
Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.
19 auth.
A. Cheng,
S. Qin,
M. Ikeda,
P. Galle,
M. Ducreux,
Tae-You Kim,
Ho Yeong Lim,
M. Kudo,
V. Breder,
P. Merle,
...
A. Kaseb,
Daneng Li,
W. Verret,
N. Ma,
A. Nicholas,
Yifan Wang,
Lindong Li,
A. Zhu,
R. Finn
|
9 |
2021 |
9
🐜
|
|
🐜
|
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
20 auth.
R. Finn,
M. Ikeda,
A. Zhu,
M. Sung,
A. Baron,
M. Kudo,
T. Okusaka,
M. Kobayashi,
H. Kumada,
S. Kaneko,
...
M. Pracht,
K. Mamontov,
T. Meyer,
T. Kubota,
C. Dutcus,
Kenichi Saito,
A. Siegel,
L. Dubrovsky,
K. Mody,
J. Llovet
|
9 |
2020 |
9
🐜
|
|
🐜
|
JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan
16 auth.
M. Kudo,
O. Matsui,
N. Izumi,
H. Iijima,
M. Kadoya,
Y. Imai,
T. Okusaka,
S. Miyayama,
K. Tsuchiya,
K. Ueshima,
...
A. Hiraoka,
M. Ikeda,
S. Ogasawara,
T. Yamashita,
T. Minami,
K. Yamakado
|
9 |
2014 |
9
🐜
|
|
🐜
|
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
25 auth.
H. Ueno,
T. Ioka,
M. Ikeda,
S. Ohkawa,
H. Yanagimoto,
N. Boku,
A. Fukutomi,
K. Sugimori,
H. Baba,
K. Yamao,
T. Shimamura,
M. Sho,
M. Kitano,
A. Cheng,
K. Mizumoto,
...
Jen‐Shi Chen,
J. Furuse,
A. Funakoshi,
T. Hatori,
Taketo Yamaguchi,
S. Egawa,
A. Sato,
Y. Ohashi,
T. Okusaka,
Masao Tanaka
|
9 |
2013 |
9
🐜
|
|
🐜
|
Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial
27 auth.
M. Kudo,
K. Ueshima,
M. Ikeda,
T. Torimura,
N. Tanabe,
H. Aikata,
N. Izumi,
T. Yamasaki,
S. Nojiri,
K. Hino,
H. Tsumura,
T. Kuzuya,
N. Isoda,
K. Yasui,
Hajime Aino,
...
A. Ido,
Naoto Kawabe,
K. Nakao,
Y. Wada,
O. Yokosuka,
K. Yoshimura,
T. Okusaka,
J. Furuse,
N. Kokudo,
K. Okita,
P. Johnson,
Y. Arai
|
8 |
2019 |
8
🐜
|
|
🐜
|
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer.
29 auth.
D. Oh,
A. Ruth He,
S. Qin,
Li‐Tzong Chen,
T. Okusaka,
A. Vogel,
J. W. Kim,
T. Suksombooncharoen,
Myung Ah Lee,
Masayuki Kitano,
H. Burris,
M. Bouattour,
S. Tanasanvimon,
M. McNamara,
R. Zaucha,
...
A. Avallone,
Benjamin Tan,
J. Cundom,
Choong-kun Lee,
Hidenori Takahashi,
M. Ikeda,
Jen‐Shi Chen,
Julie Wang,
M. Makowsky,
N. Rokutanda,
P. He,
J. Kurland,
G. Cohen,
J. Valle
|
8 |
2022 |
8
🐜
|
|
🐜
|
Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update
25 auth.
M. Kudo,
Y. Kawamura,
K. Hasegawa,
R. Tateishi,
K. Kariyama,
S. Shiina,
H. Toyoda,
Y. Imai,
A. Hiraoka,
M. Ikeda,
N. Izumi,
M. Moriguchi,
S. Ogasawara,
Y. Minami,
K. Ueshima,
...
T. Murakami,
S. Miyayama,
O. Nakashima,
H. Yano,
M. Sakamoto,
E. Hatano,
M. Shimada,
N. Kokudo,
S. Mochida,
T. Takehara
|
8 |
2021 |
8
🐜
|
|
🐜
|
Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma
12 auth.
K. Ikeda,
M. Kudo,
S. Kawazoe,
Y. Osaki,
M. Ikeda,
T. Okusaka,
...
T. Tamai,
Takuya Suzuki,
T. Hisai,
S. Hayato,
K. Okita,
H. Kumada
|
8 |
2016 |
8
🐜
|
|
🐜
|
Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study
24 auth.
R. Kelley,
B. Sangro,
W. Harris,
M. Ikeda,
T. Okusaka,
Yoon-Koo Kang,
S. Qin,
D. Tai,
Ho Yeong Lim,
T. Yau,
...
W. Yong,
A. Cheng,
A. Gasbarrini,
S. Damian,
J. Bruix,
M. Borad,
J. Bendell,
Tae-You Kim,
N. Standifer,
P. He,
M. Makowsky,
A. Negro,
M. Kudo,
G. Abou-Alfa
|
8 |
2021 |
8
🐜
|
|
🐜
|
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies
39 auth.
Y. Nakamura,
H. Taniguchi,
M. Ikeda,
H. Bando,
Ken Kato,
C. Morizane,
T. Esaki,
Y. Komatsu,
Y. Kawamoto,
N. Takahashi,
M. Ueno,
Y. Kagawa,
T. Nishina,
Takeshi Kato,
Yoshiyuki Yamamoto,
...
J. Furuse,
T. Denda,
H. Kawakami,
E. Oki,
T. Nakajima,
N. Nishida,
K. Yamaguchi,
H. Yasui,
M. Goto,
N. Matsuhashi,
K. Ohtsubo,
K. Yamazaki,
A. Tsuji,
W. Okamoto,
K. Tsuchihara,
T. Yamanaka,
I. Miki,
Y. Sakamoto,
H. Ichiki,
Masayuki Hata,
R. Yamashita,
A. Ohtsu,
J. Odegaard,
T. Yoshino
|
7 |
2020 |
7
🐜
|
|
🐜
|
Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study.
12 auth.
M. Ueno,
M. Ikeda,
C. Morizane,
Satoshi Kobayashi,
I. Ohno,
S. Kondo,
...
N. Okano,
K. Kimura,
S. Asada,
Y. Namba,
T. Okusaka,
J. Furuse
|
7 |
2019 |
7
🐜
|
|
🐜
|
Transarterial Chemoembolization Failure/Refractoriness: JSH-LCSGJ Criteria 2014 Update
14 auth.
M. Kudo,
O. Matsui,
N. Izumi,
M. Kadoya,
T. Okusaka,
S. Miyayama,
K. Yamakado,
K. Tsuchiya,
K. Ueshima,
A. Hiraoka,
...
M. Ikeda,
S. Ogasawara,
T. Yamashita,
T. Minami
|
7 |
2014 |
7
🐜
|
